Market Overview

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates For The Next Quarter

Related ABAX
15 Biggest Mid-Day Losers For Tuesday
Canaccord Fireside Chat Takeaways For Abaxis, Heska
Related VIVO
15 Biggest Mid-Day Losers For Wednesday
Mid-Afternoon Market Update: Seagate Climbs On Strong Q2 Results; Meridian Bioscience Shares Plummet
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ... (GuruFocus)

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of earnings estimate for the next quarter.

Abaxis (NASDAQ: ABAX) is estimated to post earnings of $0.24 per share in the June quarter. Abaxis' trailing-twelve-month revenue is $178.79 million.

Meridian Bioscience (NASDAQ: VIVO) is expected to earn $0.22 per share in the June quarter. Meridian Bioscience's trailing-twelve-month operating margin is 29.72%.

SurModics (NASDAQ: SRDX) is likely to earn $0.22 per share in the June quarter. SurModics had $30.96 million in total cash for the latest quarter.

Trinity Biotech plc (NASDAQ: TRIB) may earn $0.20 per share in the March quarter. Trinity Biotech's PEG ratio is 1.88.

Posted-In: Diagnostic Substances Industry Highest EPS Estimates small-cap stocksTrading Ideas


Related Articles (ABAX + SRDX)

View Comments and Join the Discussion!

Partner Center